Letrozole in the Treatment of Advanced Breast Cancer

  • P. Pronzato
  • A. Tognoni
Conference paper


Advanced metastatic breast cancer is commonly considered as an incurable disease. In spite of the high rate of objective remissions achieved with the most recent polychemotherapy regimens or hormonal manipulations, the duration of response is limited, the disease progresses and, after a median interval of 24–36 months from the appearance of clinically detectable metastases, the patients inexorably die from cancer. Currently, there are two broad categories of treatment for metastatic breast cancer: cytotoxic chemotherapy and hormonal treatment. Women who are known to have a hormone-dependent tumor usually receive hormonal therapies, as these are better tolerated than chemotherapy.


Breast Cancer Clin Oncol Metastatic Breast Cancer Aromatase Inhibitor Advanced Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2002). Anastrozole alone or in combination with tamoxifen vs. tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131–2139.CrossRefGoogle Scholar
  2. Buzdar A.U. (2001). A summary of second-line randomised studies of aromatase inhibitors. J Steroid Biochem Mol Biol, 79, 10–114.CrossRefGoogle Scholar
  3. Day R., Ganz P.A. and Constantino J.P. (1999). Health-related quality of life and tamoxifen in breast cancer prevention. A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol, 17, 2659–2669.PubMedGoogle Scholar
  4. Demissie S., Silliman R.A. and Lash T.L. (2001). Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol, 19, 322–328.PubMedGoogle Scholar
  5. Dombernowsky P. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer. Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol, 16, 453–461.PubMedGoogle Scholar
  6. Early Breast Cancer Trialists Collaborative Group (1992). Systemic treatment of earlyGoogle Scholar
  7. breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrencies and 24,000 deaths among 75,000 women. Lancet, 339, 1–15Google Scholar
  8. Eiermann W., Paepke S. and Appfelstaedt J. (2001). Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol, 12, 1527–1532.PubMedCrossRefGoogle Scholar
  9. Elisaf M.S., Bairaktari E.T. and Niolaides C. (2001). Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer, 37, 1510–1513.PubMedCrossRefGoogle Scholar
  10. Ellis M.J., Coop A. and Singh B. (2001). Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or Erbb-z-positive, estrogen receptor-positive primary: evidence from a phase III randomized trial. J Clin Oncol, 19, 3808–3816.PubMedGoogle Scholar
  11. Fallowfield L., Fleissig A. and Edwards R. (2001). Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol, 19, 1885–1892.PubMedGoogle Scholar
  12. Ganz P.A., Day R. and Ware J.E. Jr (2001). Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project prevention (Pvi) randomized study. J Natl Cancer Inst, 93, 1615–1623.PubMedCrossRefGoogle Scholar
  13. Gershanovich M. (1998). Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol, 9, 639–645.PubMedCrossRefGoogle Scholar
  14. Goss P.E. and Strasser K. (2001). Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol, 19, 881–894.PubMedGoogle Scholar
  15. Gruber C.J., Tschugguel W., Schneeberger C. and Huber J.C. (2002). Production and actions of estrogens. N Rugl J Med, 346, 340–352.CrossRefGoogle Scholar
  16. Hamilton A. and Piccart M. (1999). The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol, 10, 377–384.PubMedCrossRefGoogle Scholar
  17. Lipton A., Ali S.M. and Keitzel K. (2002). Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol, 20, 1467–1472.PubMedCrossRefGoogle Scholar
  18. Merlano M.C. (2002). Maintenace therapy with letrozole after first-line chemotherapy in advanced breast cancer: the MANTLE trial. 38th ASCO, Orlando (FL), May 18–21, Abstract 1996, 46b.Google Scholar
  19. Mortimer J.E., Boucher L. and Knapp D.L. (1999). Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol, 17, 1488–1492.PubMedGoogle Scholar
  20. Mouridsen H., Gershanovic M. and Sun Y. (2001). Superior efficacy of letrozole vs. tamoxifen as first-line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 19, 2596–2606.PubMedGoogle Scholar
  21. Robertson J.P.R., Willsher P.C., Cheung K.L. and Blarney R.W. (1997). The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer, 33, 1774–1779.PubMedCrossRefGoogle Scholar
  22. Rose C. (2002). Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. 38th ASCO, Orlando (FL), May 18–21, Abstract 131, 34a.Google Scholar
  23. Thomas R. (2002). Empowering patients to make informed treatment decisions based on tolerability, quality of life patient preference. A comparison of letrozole and anastrozole in a multicentre randomised, single-blind cross over study. EBCC, Barcelona, Spain, March 2002, 200, Abstract 171.Google Scholar
  24. Thurlimann J.B., Hsu Schmitz S.P. and Castiglione-Gersch M. (1999). Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol, 17, 1672–1679.PubMedGoogle Scholar
  25. Yamauchi H., Stearns V. and Hayes D.P.(2001): When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol, 19, 2234–2356.Google Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • P. Pronzato
  • A. Tognoni

There are no affiliations available

Personalised recommendations